<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01778439</url>
  </required_header>
  <id_info>
    <org_study_id>52M51-002</org_study_id>
    <nct_id>NCT01778439</nct_id>
  </id_info>
  <brief_title>A Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors</brief_title>
  <official_title>A Phase 1 Dose Escalation Study of OMP-52M51 in Subjects With Solid Tumors</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>OncoMed Pharmaceuticals, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Mereo BioPharma</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This is an open-label Phase 1a dose escalation study of single-agent OMP-52M51 in subjects&#xD;
      with relapsed or refractory solid tumors. Study includes a dose escalation phase and&#xD;
      expansion phase. Subjects will be assessed for safety, immunogenicity, pharmacokinetics,&#xD;
      biomarkers, and efficacy.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>February 2013</start_date>
  <completion_date type="Actual">July 2016</completion_date>
  <primary_completion_date type="Actual">July 2016</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Safety profile of OMP-52M51 in subjects with relapsed or refractory solid tumors</measure>
    <time_frame>Subjects will be assessed for DLTs from Days 0-29. Adverse events will be reported through 30 days after the last dose</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetics (PK) of OMP-52M51 in subjects with relapsed or refractory solid tumors</measure>
    <time_frame>PK analyses at various time points following the 1st and 2nd doses, immediately pre and post-dose for all subsequent doses at treatment term, every 4 weeks after discontinuation of study drug or 12 weeks</time_frame>
    <description>Apparent half life, AUC, clearance, volume of distribution</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Immunogenicity</measure>
    <time_frame>Assessed at baseline, prior to each dose, at treatment termination and every 4 weeks after the discontinuation of the study drug for 12 weeks.</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Preliminary Efficacy</measure>
    <time_frame>Evaluation for response will be assessed on day 70 of study and every 8 weeks (or 9 weeks for Q3W schedule) thereafter and will be based on RECIST v1.1.</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">48</enrollment>
  <condition>Relapsed or Refractory Solid Tumors</condition>
  <arm_group>
    <arm_group_label>OMP-52M51</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>OMP-52M51</intervention_name>
    <arm_group_label>OMP-52M51</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects must meet all of the following criteria to be eligible for the study:&#xD;
&#xD;
          1. Age &gt;18 years&#xD;
&#xD;
          2. ECOG performance status &lt;2 (see Appendix B)&#xD;
&#xD;
          3. Solid tumor malignancy for which there is no remaining standard therapy or either&#xD;
             refuse or are not considered to be candidates for any remaining standard therapy.&#xD;
&#xD;
          4. Must have a tumor that is measurable or evaluable per RECIST v1.1 in the dose&#xD;
             escalation phase. In the expansion cohort(s), subjects must have measurable disease.&#xD;
&#xD;
          5. Subjects must have Formalin-Fixed, Paraffin-Embedded (FFPE) tissue available either&#xD;
             archived or fresh core or punch needle biopsied at study entry (two fresh&#xD;
             cores/punches preferred whenever possible) for determination of Notch1 pathway&#xD;
             activation status.&#xD;
&#xD;
          6. Must have received their last chemotherapy, biologic, radiotherapy, or investigational&#xD;
             therapy at least 4 weeks prior to enrollment; 6 weeks if the last regimen included&#xD;
             BCNU or mitomycin C.&#xD;
&#xD;
          7. Subjects must have normal organ and marrow function as defined below:&#xD;
&#xD;
               -  Absolute neutrophil count &gt;1500/mL without growth factor support in the past 7&#xD;
                  days&#xD;
&#xD;
               -  Platelets &gt;100,000/mL without transfusions in the past 7 days&#xD;
&#xD;
               -  Total bilirubin &lt;1.5 X institutional upper limit of normal (ULN) (&lt;2X ULN for&#xD;
                  subjects with Gilbert's syndrome)&#xD;
&#xD;
               -  AST (SGOT) and ALT (SGPT) &lt;3 X institutional ULN (for subjects with hepatic&#xD;
                  involvement &lt;5 X institutional ULN but cannot be associated with elevated&#xD;
                  bilirubin)&#xD;
&#xD;
               -  PT/INR and aPTT within 1.5 X institutional ULN&#xD;
&#xD;
               -  Creatinine &lt;1.5 X institutional ULN OR&#xD;
&#xD;
               -  Creatinine clearance &gt;60 mL/min/1.73 m2 for subjects with creatinine levels above&#xD;
                  institutional normal&#xD;
&#xD;
               -  Normal Ejection Fraction (&gt;50%) on ECHO scan or MUGA&#xD;
&#xD;
          8. Women of childbearing potential must have had a prior hysterectomy or have a negative&#xD;
             serum pregnancy test and be using adequate contraception prior to study entry and must&#xD;
             agree to use adequate contraception from study entry through at least 6 months after&#xD;
             discontinuation of study drug. Men must also agree to use adequate contraception&#xD;
             (hormonal or barrier method of birth control; abstinence) prior to study entry and&#xD;
             from study entry through at least 6 months after discontinuation of study drug. Should&#xD;
             a woman enrolled in the study or a female partner of a man enrolled in the study&#xD;
             become pregnant or suspect she is pregnant while participating in this study or within&#xD;
             6 months after discontinuation of study, she should inform the Investigator&#xD;
             immediately.&#xD;
&#xD;
          9. Ability to understand and the willingness to sign a written informed consent document&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects who meet any of the following criteria will not be eligible for participation in&#xD;
        the study:&#xD;
&#xD;
          1. Currently receiving any therapeutic treatment for their malignancy including other&#xD;
             investigational agents&#xD;
&#xD;
          2. Prior treatment with gamma secretase inhibitors or other Notch 1 inhibitors&#xD;
&#xD;
          3. Uncontrolled seizure disorder, active neurologic disease, or active CNS involvement&#xD;
             except for individuals who have previously-treated CNS metastases, are asymptomatic,&#xD;
             and have no requirement for higher doses of corticosteroids (&gt; prednisone 10mg orally&#xD;
             per day) or anti-seizure medication for at least 4 weeks prior to first dose of study&#xD;
             drug.&#xD;
&#xD;
          4. History of a Grade 4 allergic reaction attributed to humanized or human monoclonal&#xD;
             antibody therapy&#xD;
&#xD;
          5. Significant intercurrent illness including, but not limited to, ongoing or active&#xD;
             infection, symptomatic congestive heart failure, unstable angina pectoris, cardiac&#xD;
             arrhythmia, or psychiatric illness/social situations that would limit compliance with&#xD;
             study requirements&#xD;
&#xD;
          6. Pregnant women or nursing women&#xD;
&#xD;
          7. Ongoing malignancies or malignancies in remission &lt;3 years other than the malignancies&#xD;
             included in this trial. Patients with history of known squamous cell skin cancers&#xD;
             within the past 3 years will not be included in this trial. The following prior&#xD;
             malignancies are allowable irrespective of when they occurred: in situ carcinoma of&#xD;
             the cervix, in situ ductal breast cancer, and low-grade local bladder cancer.&#xD;
&#xD;
          8. Subjects with known HIV infection&#xD;
&#xD;
          9. Known bleeding disorder or coagulopathy&#xD;
&#xD;
         10. Known endobronchial lesions and/or lesions infiltrating major pulmonary vessels.&#xD;
&#xD;
         11. Hemoptysis in excess of 2.5 mL(or one-half teaspoon) within 8 weeks of first dose of&#xD;
             study drug.&#xD;
&#xD;
         12. Subjects receiving heparin, warfarin, or other similar anticoagulants, except for&#xD;
             subjects on low molecular weight heparin for DVT/PE prophylaxis. Note: Subjects may be&#xD;
             receiving low-dose aspirin and/or non-steroidal anti-inflammatory agents.&#xD;
&#xD;
         13. New York Heart Association Classification II, III, or IV (see Appendix D)&#xD;
&#xD;
         14. Subjects with poorly controlled blood pressure (defined as systolic blood pressure&#xD;
             ≥140 mmHg or diastolic blood pressure ≥90 mmHg) that is not responsive to medical&#xD;
             therapy. Subjects taking antihypertensive medications must be taking ≤2 medications to&#xD;
             obtain this level of blood pressure control.&#xD;
&#xD;
             NOTE: Initiation or adjustment of antihypertensive medication(s) is permitted prior to&#xD;
             study entry.&#xD;
&#xD;
         15. Subjects with ECG evidence of ischemia or ≥Grade 2 ventricular arrhythmia, subjects&#xD;
             who have a history of acute myocardial infarction within 6 months, or subjects with&#xD;
             unstable angina.&#xD;
&#xD;
         16. Subjects with known clinically significant gastrointestinal disease including, but not&#xD;
             limited to:&#xD;
&#xD;
               -  inflammatory bowel disease&#xD;
&#xD;
               -  active peptic ulcer disease&#xD;
&#xD;
               -  known intraluminal metastatic lesion(s) with risk of bleeding&#xD;
&#xD;
               -  history of abdominal fistula, GI perforation, or intra-abdominal abscess within&#xD;
                  28 days prior to beginning study treatment&#xD;
&#xD;
         17. Subjects with diarrhea at time of enrollment or have an ongoing requirement for anti&#xD;
             diarrheal therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>90 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>University of California, San Francisco/Helen Diller Cancer Institute</name>
      <address>
        <city>San Francisco</city>
        <state>California</state>
        <zip>94115</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University of Colorado Denver -RCI-South Tower</name>
      <address>
        <city>Aurora</city>
        <state>Colorado</state>
        <zip>80045</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Karmanos Cancer Institute (KCI)</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Wayne State University/Oncology Karmanos Cancer Institute</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48201</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The University of Texas MD Anderson Cancer Center</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77030</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>South Texas Accelerated Research Therapeutics, LLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>January 24, 2013</study_first_submitted>
  <study_first_submitted_qc>January 28, 2013</study_first_submitted_qc>
  <study_first_posted type="Estimate">January 29, 2013</study_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Phase 1</keyword>
  <keyword>Dose escalation</keyword>
  <keyword>relapsed or refractory</keyword>
  <keyword>solid tumor</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Neoplasms</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

